

ÖZGEÇMİŞ VE ESERLER LİSTESİ

ÖZGEÇMİŞ

Adı Soyadı: Berrin Pehlivan

Doğum Tarihi: 22/12/1976

Mail adresi: berrinpehlivan@gmail.com

Telefon: 0 532 402 47 27

Öğrenim Durumu:

Derece	Bölüm/Program	Üniversite	Yıl
Lisans	Tıp Fakültesi	Hacettepe Üniversitesi	1993
Doktora/S.Yeterlik/ Tıpta Uzmanlık	Radyasyon Onkolojisi	Hacettepe Üniversitesi	2001
Yüksek Lisans	MBA (Master for Business Administration)	Antalya Bilim Üniversitesi	2014- 2016

Doktora Tezi/S.Yeterlik Çalışması/Tıpta Uzmanlık Tezi Başlığı (özeti ekte) ve Danışman(lar)ı :

Serviks kanserli 166 hastada postoperatif radyoterapi sonuçları.

Tez Danışmanı: Prof.Dr. İ. Lale Atahan

Yabancı Dil: İngilizce, Fransızca

Görevler:

Görev Unvanı	Görev Yeri	Yıl
Araştırma Görevlisi	Radyasyon Onkolojisi Anabilim Dalı, Hacettepe Üniversitesi Tıp Fakültesi	Temmuz 2001- Ekim 2004
Araştırma Görevlisi	Avrupa Kanseroloji Diploma Programı (DUERCC), Institute Gustave Roussy, Paris, Fransa	Kasım 2004- Mart 2006
Araştırma Görevlisi	Radyasyon Onkolojisi Anabilim Dalı, Centre Hospitalier Vaudois, Lozan, İsviçre	Nisan 2006- Mart 2007
Visiting Scientist	Protonterapi Merkezi, Paul Scherrer Enstitüsü, Villigen/İsviçre	Ağustos 2007- Mart 2008

Visiting Scientist	Institute Curie Orsay Protonterapi Merkezi, Orsay/Fransa	Nisan 2008- Ekim 2008
Öğretim Görevlisi	Radyasyon Onkolojisi, Başkent Üniversitesi, Adana Kışla Sağlık Yerleşkesi	Ocak 2009- Şubat 2010
Yrd Doç. Dr Doç. Dr.	Radyasyon Onkolojisi, Akdeniz Üniversitesi, Antalya Radyasyon Onkolojisi, Akdeniz Üniversitesi, Antalya	Mart 2010- 9 Nisan 2012
Yeterlilik	Türk Radyasyon Onkolojisi Derneği	2011
Doç. Dr.	Radyasyon Onkolojisi, Memorial Sağlık Grubu, Medstar Antalya Hastanesi	9 Nisan 2012 – Şubat 2015
Doç. Dr.	Radyasyon Onkolojisi, Medical Park Sağlık Grubu Göztepe ve Bahçelievler Hastaneleri Radyasyon Onkolojisi, Altınbaş Üniversitesi	Nisan 2015- Mayıs 2017
Prof. Dr.	Radyasyon Onkolojisi, Medical Park Sağlık Grubu Göztepe ve Bahçelievler Hastaneleri Radyasyon Onkolojisi, Altınbaş Üniversitesi	Mayıs 2017- Haziran 2018
Prof. Dr.	Bahçeşehir Üniversitesi, Radyasyon Onkolojisi	Temmuz 2018-

Yayınlar

1. Somay E, Topkan E, Bascil S, Kılıc Durankuş N, Senyürek Ş, Ozturk D, **Pehlivan B**, Selek U. Global Immune-Nutrition-Inflammation Index as a novel comprehensive biomarker in predicting the radiation-induced trismus rates in locally advanced nasopharyngeal carcinoma patients. Biomol Biomed. 2024 Jun 10 Global Immune-Nutrition-Inflammation Index as a novel comprehensive biomarker in predicting the radiation-induced trismus rates in locally advanced nasopharyngeal carcinoma patients - PubMed (nih.gov)
2. Topkan E, Kucuk A, Ozturk D, Ozkan EE, Besen AA, **Pehlivan B**, Selek U. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy. Can Respir J. 2024 Jun 28;2024:2803044. Prognostic Value of Novel CARWL Score in Stage IIIC Non-

Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy - PubMed (nih.gov)

3. Somay E, Topkan E, Selek U, **Pehlivan B**. Comment on 'accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID-19 pandemic: A tertiary care experience'. J Cancer Res Ther. 2024 Apr 1;20(3):1106-1107 Comment on 'accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID-19 pandemic: A tertiary care experience' - PubMed (nih.gov)
4. Somay E, Topkan E, Kucuk A, Ozturk D, Ozkan EE, Ozdemir BS, Besen AA, Mertsoylu H, **Pehlivan B**, Selek U. Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients. J Stomatol Oral Maxillofac Surg. 2024 Mar 20:101838. Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients - PubMed (nih.gov)
5. Somay E, Topkan E, Selek U, **Pehlivan B**. Comment on " Impact of pretreatment quality of life on tolerance and survival outcome in head and neck cancer patients undergoing definitive CCRT". J Formos Med Assoc. 2024 Feb 26:S0929-6646(24)00137-2. Comment on " Impact of pretreatment quality of life on tolerance and survival outcome in head and neck cancer patients undergoing definitive CCRT" - PubMed (nih.gov)
6. Yilmaz B, Somay E, Topkan E, **Pehlivan B**, Besen AA, Mertsoylu H, Selek U. Predictive potential of pan-immune-inflammation value / hemoglobin index as biomarker for osteoradionecrosis risk in locally advanced nasopharyngeal carcinomas. J Stomatol Oral Maxillofac Surg. 2024 Jan 28;125(6):101786.
7. Somay E, Topkan E, Pehlivan UA, Yilmaz B, Besen AA, Mertsoylu H, **Pehlivan B**, Selek U. The Use of Pre-Chemoradiotherapy Total Masseter Muscle Volume as a Novel Predictor of Radiation-Induced Trismus in Locally Advanced Nasopharyngeal Carcinoma Patients. Tomography. 2024 Jan 10;10(1):79-89.

8. Topkan E, Somay E, **Pehlivan B**, Selek U. Comment on Konishi et al. Oral Radiol. 2024 Apr;40(2):327-328.
9. Topkan E, Kucuk A, Ozkan EE, Ozturk D, Besen AA, Mertsoylu H, **Pehlivan B**, Selek U. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer. Discov Oncol. 2023 Dec 13;14(1):230.
10. Topkan E, Somay E, Selek U, **Pehlivan B**. Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. Eur J Cancer. 2024 Mar;200:113459.
11. Yilmaz B, Somay E, Topkan E, **Pehlivan B**, Selek U. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2023 Feb 7.
12. Somay E, Yilmaz B, Topkan E, Kucuk A, **Pehlivan B**, Selek U. Initial neutrophil-to-lymphocyte ratio predicts radiation-induced trismus in parotid gland cancer. Oral Dis. 2022 Nov 8.
13. Somay E, Yilmaz B, Topkan E, Kucuk A, Haksoyler V, **Pehlivan B**, Selek U, Araz K. Hemoglobin-to-platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy. Oral Dis 2022 Aug 29.
14. Topkan E, Selek U, Kucuk A, **Pehlivan B**. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. J Inflamm Res. 2022 Sep 18;15:5413-5423.
15. Topkan E, Selek U, Haksoyler V, Kucuk A, Durankus NK, Sezen D, Bolukbasi Y, Pehlivan B. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers. Int J Clin Pract. 2022 Jan 31;2022:7473649.
16. Yalcin K, **Pehlivan B**, Celen S, Bas EG, Kabakci C, Pashayev D, Daloglu H, Zhumatayev S, Uygun V, Karasu GT, Hazar V, Yesilipek A. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol 2021 Mar 31.

17. Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, **Pehlivan B**. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients. *Ther Clin Risk Manag*. 2022 Apr 14;18:421-428.
18. Topkan E, Selek U, Küçük A, Haksöyler V, Özdemir Y, Sezen D, Mertsoylu H, Besen AA, Bölükbaşı Y, Özyılkan O, **Pehlivan B**. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis. *J Oncol* 2021 Jan 23;2021.
19. Küçük A, Ozkan EE, Öztep SE, Mertsoyle H, **Pehlivan B**, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. *J Oncol* 2020 Dec 16.
20. Topkan E, Besen AA, Mertsoylu H, Kucuk A, **Pehlivan B**, Selek U. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. *Int J Inflam*. 2020 Jun 8;2020.
21. Topkan E, Mertsoylu H, Kucuk A, Besen AA, Sezer A, Sezen D, Bolukbasi Y, Selek U, **Pehlivan B**. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. *Gastroenterol Res Pract*. 2020 Jul 30;2020.
22. Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, Sezen D, Akdemir EY, Sezer A, Bolukbasi Y, **Pehlivan B**, Selek U. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study. *J Oncol*. 2020 Sep 4;2020.
23. Topkan E, Kucuk A, Ozdemir Y, Mertsoylu H, Besen AA, Sezen D, Bolukbasi Y, **Pehlivan B**, Selek U. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. *J Immunol Res*. 2020 Nov 14;2020.
24. Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, **Pehlivan B**, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. *J Oncol* 2020 Dec 16;2020.

25. Topkan E, Besen AA, Ozdemir Y, Kucuk A, Mertsoylu H, **Pehlivan B** and Selek U. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Post-neurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020 23;2020.
26. Kucuk A, Topkan E, İkiz ED, Durankuş N, Senyurek S, Aydemir EY, Sezen D, Bolukbaşı Y, Selek U, **Pehlivan B**. Combination of stereotactic radiosurgery with immunotherapy: is it a new treatment option for brain metastases? Int Res J Oncol, 2020.
27. Topkan E, Küçük A, Şenyürek S, Sezen D, Durankuş NK, Aydemir EY, İkiz ED, Bölükbaşı Y, **Pehlivan B** ve Selek U. Preoperative radiosurgery in management of brain metastases. J Cancer Tumor Int, 10(1):1-11, 2020.
28. Topkan E, Küçük A, Sezen D, Senyürek S, Aydemir EY, Durankuş N, İkiz ED, Bolukbaşı Y, **Pehlivan B** ve Selek U. Common prognostic scoring system for patients presenting with brain metastases. Clin Oncol Res, 2020.
29. **Pehlivan B**, Topkan E, Küçük A, Okumuş A, Sezen D, Bölükbaşı Y, Selek U. Stereotactic radiosurgery and targeted therapies for brain metastases from solid cancers. JAMMR,ISSN:2456-8899.
30. Topkan E, Küçük A, Durankuş NK, Şenyürek Ş, Akdemir EY, Sezen D, İkiz ED, Bölükbaşı Y, **Pehlivan B**, Selek U. Radiosurgical management of brainstem metastasis. Int Res J Oncol, 2020 3(1):37-46.
31. Sağlam Y, Bölükbaşı Y, Atasoy Aİ, Karaköse F, Alpan V, Selek U, Küçük A, **Pehlivan B**, Topkan E. Quality assurance in stereotactic radiosurgery and stereotactic body radiotherapy. Advances in Research 21 (7), 22-33.
32. Topkan E, Küçük A, Şenyürek Ş, Sezen D, Durankuş NK, Akdemir EY, Sağlam Y, Bölükbaşı Y, **Pehlivan B**, Selek U. Radiosurgery techniques for brain metastases. JCTI 2020; 10, 1-14.
33. Bölükbaşı Y, Selek U, Sezen D, Durankuş NK, Akdemir EY, Şenyürek Ş, Küçük A, **Pehlivan B**, Topkan E. Tumor cavity stereotactic radiosurgery for resected brain metastases. JCTI 2020, 10(2):15-30.
34. **Pehlivan B**, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y, Topkan E. Dosimetric comparison of lung-sparing radiation therapy between volumetric arc therapy and helical tomotherapy for unresectable malignant pleural mesothelioma. BioMed Res Int, 2019.
35. **Pehlivan B**, Kucuk A, Mertsoylu H, Topkan E. Current management of brainstem gliomas. Int. J.Adv. Res. 7(9), 2019.

36. Topkan E, **Pehlivan B**. Radiation-induced abscopal effects on cardiovascular system. *IndJMedResPharmSci*, 6(9), 2019.
37. Golusinski P, Di Maio P, **Pehlivan B**, Colley S, Nankivell P, Kong A, Hartley A, Mehanna H. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. *Oral Oncol*. 2019 Jan;88:145-152.
38. Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcioğlu A, Ozyılkan O, **Pehlivan B**. Risk factors for .fatal pulmonary hemorrhage following concurrent chemoradiotherapy in stage 3B/C squamous-cell lung carcinoma patients. *J Oncol* 2018 Nov 1;2018.
39. Topkan E, Yildirim BA, Guler OC, Parlak C, **Pehlivan B**, Selek U. Safety and palliative efficacy of single-dose-8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. *Int J Radiat Oncol Biol Phys*. 2015 Mar 15;91(4):774-80.
40. Duman E, Cecen Y, Sındır B, Ozdemir B, Yıldırım M, Cecen S, **Pehlivan B**, Yavuz MN. Dosimetric evaluation of Adaptive Therapy in non-small lung cancer patients undergoing palliative thoracic Radiotherapy. *Int J Hematol Oncol*. 2015, 25:178-185.
41. Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick, **Pehlivan B**, Krengli M, Pellanda AF, Vess H. Cai L, Scandolaro L, Belacemi Y, Villa S, Igdem S, Lutsyk M, Miller RC. History of rare cancer network and past research. *Rare Tumors*. 2014 Aug 6;6(3):5462.
42. Sarıca FB, Çekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H, Topkan E, **Pehlivan B**, Erdoğan B, Altınors B. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. *Asian J Neurosurg*. 2012 Oct;7(4):181-90.
43. Topkan E, Parlak C, Topuk S, **Pehlivan B**. Influence on oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. *BMC Cancer* 2012 Oct 31;12:502.
44. **Pehlivan B**, Ares C, Lomax T, Stadelmann O, Goitein G, Timmermann B, Schneider RA, Hug EB.: Temporal lobe toxicity analysis after proton radiation therapy for skull base tumors. *Int J Radiat Oncol Biol Phys* 2012 Aug 1;83(5):1432-40.
45. Topkan E, Parlak C, Kotek A, Yuksel O, Cengiz M, Ozsahin M, **Pehlivan B**. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB

non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens. Int J Radiat Oncol Biol Phys 2012 July 15;83(4):1264-71.

46. **Pehlivan B**, Onal C, Yavuz M.: Retinoblastoma Tedavisinde Eksternal Radyoterapinin Rolü ve Radyoterapi Seçenekleri. Int J. Hematol Oncol. 2012, 22(2):1-9.
47. Topkan E, Parlak C, Kotek A, Yapar AF, **Pehlivan B**. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011 10,11:123.
48. Topkan E, Topuk S, Oymak E, Parlak C, **Pehlivan B**. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012; 35(3):284-9.
49. Sarıca F, Tufan K, Çekinmez M, Şen O, Onal HC, Mertsoylu H, **Pehlivan B**, Erdoğan B, Altınors MN. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide: concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010; 54(1): 7-19.
50. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, **Pehlivan B**, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A.: Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):992-7.
51. Yavuz MN, Topkan E, Yavuz AA, Aydın M, Onal C, Reyhan M, Kotek A, **Pehlivan B**, Yapar AF.: FDG-PET/CT Imaging-based target volume delineation for preoperative conformal radiotherapy for rectal carcinoma. Int J Hematol Oncol 2010, 20(2):067-074.
52. **Pehlivan B**, Topkan E, Onal C, Nursal GN, Yüksel O, Yavuz M, Yavuz A.: Comparison of CT and integrated PET-CT based radiation therapy planning in malignant pleural mesothelioma patients. Radiat Oncol. 2009, 4:35.
53. **Pehlivan B**, Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M.: Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. Ann Surg Oncol. 2009, 16:1337-1343.
54. **Pehlivan B**, Pichenot C, Castiglioni M, Aupey A, Arriagada R, Bourhis J.: Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol. 2009, 48(3):440-5.

55. **Pehlivan B**, Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, Matzinger O, Mirimanoff RO, Ozsahin M.: Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy. *Ann Surg Oncol.* 2009, 16:1331-1336.
56. Onal C, Arslan G, Topkan E, **Pehlivan B**, Yavuz M, Oymak E, Yavuz A.: Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses. *J Exp Clin Cancer Res.* 2009 Jul 1;28:95.
57. Onal C, **Pehlivan B**, Bal N, Topkan E, Kilinc F, Topuk S. : Sarcomatoid Carcinoma of the Urinary Bladder Treated with Adjuvant Radiotherapy: A Case Report. *Clinical Medicine: Case Reports* 2009;2 39-42.
58. Onal C, Yuksel O, Topkan E, **Pehlivan B**. : Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: case report. *Cases Journal* 2009, 2:8402.
59. Atahan IL, Yıldız F, Ozyar E, **Pehlivan B**, Genç M, Köse M, Tulunay G, Ayhan A, Yuce K, Güler N, Kucukali T.: Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. *Int J Gynecol Cancer* 2007, 17 (4): 813-820.
60. Garcia R, Bourhis J, **Pehlivan B**, Pichenot C, Alfonsi M.: Intensity modulated radiotherapy for cancers of the upper aerodigestive tract. *Cancer Radiother* 2007, 11(6-7):353-7.
61. **Pehlivan B**, Topkan E, Yavuz A.: Protontherapy in clinical use. *Ege Tıp Dergisi*, 50(1):1-6, 2011